MetaCap

Larimar Therapeutics (LRMR) vs ARS Pharmaceuticals (SPRY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Larimar Therapeutics (LRMR) has outperformed ARS Pharmaceuticals (SPRY) over the past year, losing 11.8% versus a loss of 61.0%. Over five years, SPRY leads with a -58.8% price change compared with -69.0% for LRMR. Larimar Therapeutics is the larger company by market cap ($328.6 million vs $297.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LRMR-11.80%SPRY-61.00%
+79%+3%-72%
Nov 21, 20251 yearNov 20, 2026
LRMR-69.37%SPRY-63.99%
+132%+18%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LRMR versus SPRY key metrics
MetricLRMRSPRY
Share price$3.14$2.96
Market cap$328.55M$297.56M
1-day change-2.48%-11.90%
YTD return-17.59%-74.59%
1-year return-11.80%-61.00%
5-year return-68.97%-58.83%
EPS (TTM)$-1.67$-2.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$84.28M
Revenue growth (YoY)—-5.46%
Net income (latest FY)$-165.67M$-171.30M
Operating margin—-212.92%
Net margin—-203.25%
52-week high$6.42$13.15
52-week low$1.92$2.44
Distance from 52-week high-51.09%-77.49%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+352.23%+474.32%
Average volume1.38M1.83M
Shares outstanding104.63M100.53M
Employees71203
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LRMR has outperformed SPRY by 49.2 percentage points over the past year.

About Larimar Therapeutics

LRMR stock →

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees

About ARS Pharmaceuticals

SPRY stock →

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.

Health Care · Biotechnology: Pharmaceutical Preparations · 203 employees

LRMR vs SPRY FAQ

Which is bigger, Larimar Therapeutics or ARS Pharmaceuticals?

Larimar Therapeutics (LRMR) is larger, with a market capitalization of $328.55M compared with $297.56M for ARS Pharmaceuticals (SPRY).

Which stock has performed better over the past year, LRMR or SPRY?

LRMR returned -11.80% over the past 12 months, compared with -61.00% for SPRY (price return, excluding dividends). Past performance does not predict future results.

Are Larimar Therapeutics and ARS Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons